Alvotech (ALVO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Alvotech (ALVO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts
Alvotech maintains at a Hold rating due to missed H1 2026 earnings and ongoing regulatory challenges, despite pipeline progress. Recent FDA CRLs for AVT05 and AVT06 were due to manufacturing issues, now addressed, with BLAs resubmitted and multiple approvals targeted for Q4 2026. AVT06, a biosimilar to EYLEA, has global commercialization rights secured post-November 2026, with patent disputes resolved and a large market opportunity.
Alvotech Q2 Earnings Call Highlights
Alvotech NASDAQ: ALVO said its first-half 2026 results reflected a temporary manufacturing slowdown tied to facility and quality-system improvements at its Reykjavik site, while management reaffirmed full-year revenue and adjusted EBITDA guidance and highlighted upcoming regulatory decisions and product launches.
Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates
Alvotech (ALVO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.14 per share a year ago.
Alvotech (ALVO) Presents at UBS Virtual Generics and Biosimilars Day Transcript
Alvotech (ALVO) Presents at UBS Virtual Generics and Biosimilars Day Transcript
Alvotech Hits Critical Inflection as Biosimilar Pipeline Nears FDA Decisions
Alvotech NASDAQ: ALVO Chief Strategy Officer Balaji Prasad said the biosimilars-focused company is entering a “critical inflection period” as it advances several limited-competition products through regulatory review and prepares for a broader launch cycle over the next several years.
Alvotech (ALVO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Alvotech (ALVO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Alvotech: Speculative 'Buy' Despite The FDA's CMC Requirements
Alvotech remains a commercial-stage biosimilar company with real revenue, partners, and a growing global footprint. I believe its main upside potential lies with the resubmission of AVT05 and AVT06 after its recent manufacturing delays in the US. ALVO's valuation has been punished by regulatory setbacks in its manufacturing facilities. So if those concerns are resolved, the stock could quickly re-rate higher.
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs
Alvotech shares surge after the company resubmits FDA applications for its biosimilar candidates, AVT05 and AVT06, with reviews expected within six months.
Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End
Alvotech NASDAQ: ALVO is at an “inflection point” after more than a decade of investment in its biosimilar platform, Founder and Executive Chairman Róbert Wessman said at the Jefferies Global Healthcare Conference in New York.
Alvotech (ALVO) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Alvotech (ALVO) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Alvotech Plans June FDA Resubmissions, Sees Biosimilar Approvals by Year-End
Alvotech NASDAQ: ALVO Chief Strategy Officer Balaji Prasad said the biosimilar developer is preparing to resubmit three biologics license applications to the U.S. Food and Drug Administration in June after addressing manufacturing observations that led to complete response letters for pipeline products.
